[Form 4] Nuvalent, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Nuvalent, Inc. (NUVL) filed a Form 4 for its Chief Financial Officer detailing option exercises and stock sales in November 2025. On November 17, 2025, the CFO exercised stock options for 6,875 Class A shares at $6.89 and 13,125 shares at $72.35, then sold multiple blocks of Class A Common Stock at weighted average prices ranging from $93.8 to $103.68. On November 18, 2025, additional options for 729 shares at $72.35 were exercised, with share sales at weighted average prices of $103.61 and $104.54. After these transactions, the CFO directly owned 61,734 Class A shares and held stock options covering 29,101 and 33,646 shares. All reported trades were made under a Rule 10b5-1 trading plan adopted on December 12, 2024.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balcom Alexandra

(Last) (First) (Middle)

C/O NUVALENT, INC.

ONE BROADWAY, 14TH FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvalent, Inc. [ NUVL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/17/2025		M(1)		6,875	A	$6.89	68,609	D
Class A Common Stock	11/17/2025		M(1)		13,125	A	$72.35	81,734	D
Class A Common Stock	11/17/2025		S(1)		3,609	D	$93.8(2)	78,125	D
Class A Common Stock	11/17/2025		S(1)		3,266	D	$95.12(3)	74,859	D
Class A Common Stock	11/17/2025		S(1)		4,496	D	$100.58(4)	70,363	D
Class A Common Stock	11/17/2025		S(1)		3,194	D	$102.13(5)	67,169	D
Class A Common Stock	11/17/2025		S(1)		5,055	D	$103.27(6)	62,114	D
Class A Common Stock	11/17/2025		S(1)		380	D	$103.68(7)	61,734	D
Class A Common Stock	11/18/2025		M(1)		729	A	$72.35	62,463	D
Class A Common Stock	11/18/2025		S(1)		220	D	$103.61(8)	62,243	D
Class A Common Stock	11/18/2025		S(1)		509	D	$104.54(9)	61,734	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.89	11/17/2025		M(1)			6,875	(10)	04/29/2031	Class A Common Stock	6,875	$0.00	29,101	D
Stock Option (Right to Buy)	$72.35	11/17/2025		M(1)			13,125	(11)	01/05/2034	Class A Common Stock	13,125	$0.00	34,375	D
Stock Option (Right to Buy)	$72.35	11/18/2025		M(1)			729	(11)	01/05/2034	Class A Common Stock	729	$0.00	33,646	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.73 to $94.38, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (9) of this Form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.93 to $95.58, inclusive.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.11 to $101.07, inclusive.

5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.57 to $102.47, inclusive.

6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.60 to $103.54, inclusive.

7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.65 to $103.79, inclusive.

8. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.14 to $103.96, inclusive.

9. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.25 to $105.12, inclusive.

10. The shares underlying this option vest as follows: 25% of the shares vested on April 29, 2022, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

11. The shares underlying this option have vested or shall vest over the four years following January 5, 2024 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

	/s/ Nathan N. McConarty, attorney-in-fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Nuvalent (NUVL) Form 4 disclose about the CFO?

The Form 4 shows that Nuvalent’s Chief Financial Officer executed multiple stock option exercises and related sales of Class A Common Stock in November 2025 and now directly owns 61,734 shares.

What stock option exercises did the Nuvalent (NUVL) CFO report?

The CFO exercised options for 6,875 shares at $6.89 and 13,125 shares at $72.35 on November 17, 2025, and 729 shares at $72.35 on November 18, 2025.

At what prices did the Nuvalent (NUVL) CFO sell shares in this Form 4?

The reported Class A share sales used weighted average prices, including $93.8, $95.12, $100.58, $102.13, $103.27, $103.68, $103.61, and $104.54, each reflecting ranges disclosed in the footnotes.

How many Nuvalent (NUVL) shares does the CFO own after the reported transactions?

Following the reported trades, the CFO directly owns 61,734 shares of Nuvalent Class A Common Stock and holds stock options over 29,101 and 33,646 underlying shares.

Were the Nuvalent (NUVL) CFO trades made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

How do the Nuvalent (NUVL) option grants vest according to the Form 4?

One option grant vested 25% on April 29, 2022, with the remainder in equal monthly installments over three years, and another vests in equal monthly installments over four years following January 5, 2024, subject to continued service.